Dr. Maiko Katadae focuses on biotech and healthcare, taking charge of due diligence in life science technol-ogies and investment operations for seed and early-stage venture enter-prises.

She invested in PeptiDream Inc. (listed in the TSE Mothers in June 2013 and the first section in December 2015) which utilizes special peptide manufacturing techniques to design new pharmaceutical drugs. She built management teams and was involved in business plans and development. She also served as an auditor.

She currently serves as a board member of Elixirgen Therapeutics, TAGCyx Biotechnologies, CREWT Medical Systems, and SOCIUM.

She is also a member of the Evaluation Committee of the Regional University Promotion and Youth Employment Creation Project of the Cabinet Office, the National Research and Development Agency Council of the Ministry of Education, and the Industrial Structure Council of METI.
Maiko graduated from the Department of Science at Ochanomizu University, and completed her master’s in Biochemistry and Ph.D. in Science at the Department of Biophysics and Biochemistry, Graduate School of Science in the University of Tokyo.

She was selected as one of the 100 Influential People of Japan in 2013 by the Nikkei Business Magazine and won the Semi-Grand Prize for Woman of the Year 2014 by Nikkei.